

1200
1000
800
600
400
200
0
MEAN TUMOR VOLUME (mm³)
0
10
20
30
40
50
60
DAYS POST TUMOR IMPLANT
Untreated
cAC10-1, 2 mg/kg
cAC10-4, 2 mg/kg
cAC10-10, 2 mg/kg
schedule: once, day 10

Figure 1



1200
1000
800
600
400
200
0
MEAN TUMOR VOLUME (mm³)
0
10
20
30
40
50
60
DAYS POST TUMOR IMPLANT
Untreated
cAC10-1, 0.6 mg/kg
cAC10-4, 0.6 mg/kg
cAC10-10, 0.6 mg/kg
schedule: once, day 7

Figure 2



1000
800
600
400
200
0
MEAN TUMOR VOLUME (mm³)
0
20
40
60
80
100
120
DAYS POST TUMOR IMPLANT
Untreated
cAC10-1, 1 mg/kg
cAC10-1, 0.5 mg/kg
cAC10-10, 1 mg/kg
cAC10-10, 0.5 mg/kg
schedule: once, day 9

Figure 3



MEAN TUMOR VOLUME (mm³)
1200
1000
800
600
400
200
0
0
10
20
30
40
50
60
70
80
DAYS POST TUMOR IMPLANT
Untreated
cAC10-1, 0.3 mg/kg, 5/6 DCRs
cAC10-1, 0.15 mg/kg, 2/5 DCRs
cAC10-10, 0.3 mg/kg, 6/6 DCRs
cAC10-10, 0.15 mg/kg, 5/6 DCRs
schedule: once, day 7

Figure 4



MEAN TUMOR VOLUME (mm³)
1200
1000
800
600
400
200
0
0
5
10
15
20
25
30
35
40
DAYS POST TUMOR IMPLANT
Untreated
cAC10-14, 0.2 mg/kg
cAC10-16, 0.2 mg/kg
schedule: once, day 7

Figure 5



MEAN TUMOR VOLUME (mm³)
1200
1000
800
600
400
200
0
0
10
20
30
40
50
60
DAYS POST TUMOR IMPLANT
Untreated
hBU12-14, 1 mg/kg
hBU12-14, 2 mg/kg
hBU12-16, 1 mg/kg
hBU12-16, 2 mg/kg
schedule: once, day 9

Figure 6



100
10
1
0.1
Total Ab µg/mL
0
5
10
15
Days
cAC10
cAC10-1
cAC10-4
cAC10-10

Figure 7



cAC10-A
7.7 min
10.4%
2 3 4 5 6 7 8 9 10 11
retention time (min)
cAC10-B
7.4 min
8.5%
2 3 4 5 6 7 8 9 10 11
retention time (min)
cAC10-C
7.2 min
3.9%
2 3 4 5 6 7 8 9 10 11
retention time (min)
cAC10-D
7.0 min
2.0%
2 3 4 5 6 7 8 9 10 11
retention time (min)
cAC10-E
6.8 min
2.0%
2 3 4 5 6 7 8 9 10 11
retention time (min)
cAC10-F
6.7 min
2.0%
2 3 4 5 6 7 8 9 10 11
retention time (min)
cAC10-G
6.6 min
2.0%
2 3 4 5 6 7 8 9 10 11
retention time (min)

Figure 8



100
10
1
0.1
0.01
Total Ab (μg/mL)
0
5
10
15
Days
cAC10-NAEM (8)
cAC10-A (8)
cAC10-K (8)
cAC10-C (8)
cAC10-L (8)

Figure 9



100
10
1
0.1
0.01
Total Ab (mg/mL)
0
5
10
15
Days
cAC10-NAEM
cAC10-A
cAC10-B
cAC10-C
cAC10-D
cAC10-H
cAC10-I
cAC10-J

Figure 10



1200
1000
800
600
400
200
0
Tumor Volume (mm³)
0
25
50
75
Days Post Tumor Implant
Untreated
cAC10-A (8)

Figure 11



1200
1000
800
600
400
200
0
Tumor Volume (mm³)
0
25
50
75
Days Post Tumor Implant
Untreated
cAC10-B (8)

Figure 12



1200
1000
800
600
400
200
0
Tumor Volume (mm³)
0
25
50
75
Days Post Tumor Implant
Untreated
cAC10-C (8)

Figure 13



1000
800
600
400
200
0
Mean Tumor Volume (mm³)
0
25
50
75
Days Post Tumor Implant
Untreated
hLIV22-K (8)
hLIV22-L (8)

Figure 14



mean tumor volume (mm3)
1000
500
0
0
20
40
60
80
100
days post implant
untreated
cAC10-1, 0.5 mg/kg
cAC10-1, 1 mg/kg
cAC10-10, 0.5 mg/kg
cAC10-10, 1 mg/kg
2/6 cures
5/6 cures
5/6 cures

Figure 15



mean tumor volume (mm3)
1000
800
600
400
200
0
0
20
40
60
80
days post implant
0/6 cures
3/6 cures
untreated
cAC10-1, 0.15 mg/kg
cAC10-1, 0.3 mg/kg
cAC10-10, 0.15 mg/kg
cAC10-10, 0.3 mg/kg

Figure 16



RL - NHL (DLCL)
% Untreated
125
100
75
50
25
0.01
0.1
1
10
100
1000
Concentration (ng/mL)
hBU12-14 (none)
hBU12-43 (PEG2)
hBU12-42 (PEG4)
hBU12-18 (PEG8)
hBU12-17 (PEG12)
hBU12-16 (PEG24)
SU-DHL-4 - NHL (DLCL)
% Untreated
125
100
75
50
25
0.01
0.1
1
10
100
1000
Concentration (ng/mL)
hBU12-14 (none)
hBU12-43 (PEG2)
hBU12-42 (PEG4)
hBU12-18 (PEG8)
hBU12-17 (PEG12)
hBU12-16 (PEG24)
WSU-DLCL-2 - NHL (DLCL)
% Untreated
125
100
75
50
25
0
0.01
0.1
1
10
100
1000
Concentration (ng/mL)
hBU12-14 (none)
hBU12-43 (PEG2)
hBU12-42 (PEG4)
hBU12-18 (PEG8)
hBU12-17 (PEG12)
hBU12-16 (PEG24)

Figure 17



Total Ab (μg/ml)
10
1
0.1
0
5
10
15
Time (days)
IgG
IgG-16 (PEG24)
IgG-17 (PEG12)
IgG-18 (PEG8)
IgG-42 (PEG4)
IgG-43 (PEG2)
IgG-44 (PEG0, Ac)
IgG-14 (none)

Figure 18



MEAN TUMOR VOLUME (mm³)
1200
1100
1000
900
800
700
600
500
400
300
200
100
0
0
10
20
30
40
50
60
70
80
90
100
DAYS POST TUMOR IMPLANT
Untreated
hBU12-14 (no PEG), 3 mg/kg
hBU12-42 (PEG4), 3 mg/kg
hBU12-18 (PEG8), 3 mg/kg
hBU12-17 (PEG12), 3 mg/kg
hBU12-16 (PEG24), 3 mg/kg
hBU12-14 (no PEG), 1 mg/kg
hBU12-42 (PEG4), 1 mg/kg
hBU12-18 (PEG8), 1 mg/kg
hBU12-17 (PEG12), 1 mg/kg
hBU12-16 (PEG24), 1 mg/kg

Figure 19



350
300
250
200
150
100
50
0
[MMAE] nM
cAC10-1
cAC10-10
cAC10-16
cAC10-4

Figure 20



10
5
0
-5
-10
-15
-20
-25
% weight change
0
5
10
Time (days)
untreated
IgG-16 (PEG24)
IgG-17 (PEG12)
IgG-18 (PEG8)
IgG-42 (PEG4)
IgG-43 (PEG2)
IgG-44 (PEG0, Ac)
IgG-14 (none)

Figure 21



PEG units
0
8
12
24
6.00
6.20
6.40
6.60
6.80
7.00
7.20
7.40
7.60
7.80
8.00
8.20
8.40
retention time (minutes)

Figure 22



elimination $t_{1/2}$ (days)
distribution $t_{1/2}$ (days)
PEG length
0
2
4
6
8
10
0.0
0.2
0.4
0.6
0.8
0
4
8
12
16
20
24
28
6.98
9.00
9.46
0.206
0.327
0.615
elimination
distribution

Figure 23